How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 1 of 2)

SAN FRANCISCO - Big pharma may need to take a leap of faith to close deals in China, accepting greater risk in areas such as regulatory compliance and quality control, according to panelists during the 29th annual J.P. Morgan Healthcare conference in San Francisco